Synonym |
Thai / English name |
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : Vecenin-2 (VCN-2)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 5 micromolarDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Docetaxel*/TaxotereDose/Conc.(drug) : 5 micromolarResult : PositiveRemark : Vecenin-2 (VCN-2) and docetaxel (DLT) co-treatment had a synergistic impact in causing significant decrease in the survival of carcinoma of prostate cells (CaP). VCN-2 and DTL induced synergistic inhibition of the clonogenic potental of CaP cells in colony-forming assay. VCN-2 alone causes down-regulation of androgen receptor and potentiates the DTL-induced decrease in androgen receptor levels.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : Vecenin-2 (VCN-2)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 10 micromolarDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Docetaxel*/TaxotereDose/Conc.(drug) : 10 micromolarResult : PositiveRemark : Vecenin-2 (VCN-2) and docetaxel (DLT) co-treatment had a synergistic impact in causing significant decrease in the survival of carcinoma of prostate cells (CaP). VCN-2 and DTL induced synergistic inhibition of the clonogenic potental of CaP cells in colony-forming assay. VCN-2 alone causes down-regulation of androgen receptor and potentiates the DTL-induced decrease in androgen receptor levels.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : Vecenin-2 (VCN-2)Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 1 mg/kgDuration : 60 daysType of interaction : PharmacodynamicsInteraction with drug : Docetaxel*/TaxotereDose/Conc.(drug) : 0.01 mg/kgResult : PositiveRemark : The combination vecenin-2 (VCN-2) and docetaxel (DTL) induced synergistic effect with significant tumor regression and reduction in tumor-weight as compared to the vehicle treated group. Alternate day oral administration of DTL along with VCN-2 was highly effective and tolerable without any overt toxicity. VCN-2 alone and in combination with DTL, up-regulated the expression of E-cadherin. The PARP-cleavage, a marker of apoptosis, was evident in VCN-2 treated groups which was further enhanced with DTL co-administration. VCN-2 decreased pAkt, pRb, PCNA, cyclin D1, fibronectin, lGF-1R levels which were further down-regulated with VCN-2 and DTL combinatorial treatment.